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Maryam Farzad Hassimi, PhD 
 
INTRODUCTION 
 Noninvasive prenatal testing (NIPT) is a screening tool for pregnant women developed in 
2011 to detect major chromosomal aneuploidies such as Trisomy 21 (Down Syndrome), Trisomy 
18 (Edwards Syndrome), and Trisomy 13 (Patau Syndrome).   In 2012, the American College of 
Obstetrics and Gynecology (ACOG) recommended NIPT for women considered high risk, and in 
August 2020 the guidelines were expanded to recommend NIPT for all pregnancies.  This news 
was praised as a dramatic shift in ensuring broader access to the highly accurate technology early 
in pregnancy.  NIPT is only a screening tool, but women have expressed overwhelming support 
for its use in prenatal care based on a low false positive rate and a reduction in the need for 
invasive diagnostic testing such as amniocentesis, which has a risk of miscarriage.   
Robust prenatal care is a key public health effort aimed at ensuring healthy pregnancies.  
As a relatively new technology, NIPT has rapidly gained positive attention along with critical 
evaluation of what public policy framework and government intervention is appropriate.  
Widespread focus on NIPT has raised concerns in four major areas that will be the focus of this 
paper.  First, NIPT is a laboratory developed test (LDT) and not an FDA-regulated in vitro 
diagnostic (IVD).  As NIPT becomes a more routine component of obstetric care, it is essential 
that the FDA expand its role in overseeing its regulation and adoption.  Second, disability 
advocates raise serious concerns about the widespread adoption of NIPT because of the 
messaging that it suggests about giving birth to and raising children with disabilities.  In 
response, public programs and legislation can continue to support their needs through various 
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measures such as ensuring resources for people living with genetic disorders.  Third, access to 
NIPT is largely determined by coverage through private insurance companies and government 
programs including Medicaid.  Variation in coverage can exacerbate existing disparities in the 
social determinants of health.  The benefits of the technology need to be proven to payers 
through studies that demonstrate the reduction of costs through fewer invasive diagnostic 
procedures and long-terms costs associated with disability. Lastly, as NIPT evolved within the 
developing field of genomics, healthcare providers such as physicians may be poorly equipped to 
understand the advances in genetic technology and properly advise pregnant women on NIPT 
results.  This complicates women’s abilities to make informed reproductive decisions.  By 
adopting NIPT into routine care, physicians are also assuming a greater legal liability when 
missing or inaccurately diagnosing a genetic screening result.  Governmental efforts to protect 
healthcare providers from lawsuits in this space will encourage more routine adoption and also 
push for more education and training in medical genetics.   
BACKGROUND 
There are approximately 4 million live births in the US yearly.1  Twenty percent are 
considered high risk based on advanced maternal age or predisposition to certain genetic 
conditions.2  Prenatal genetic testing is a key part of obstetric care for pregnant women.  
Approximately 3% of live births have a major congenital abnormality based on genetic factors.3  
Humans have two copies of chromosomes, and errors in cell division can lead to aneuploidies, 
which are the presence or absence of one or more chromosomes.  The most common 
chromosomal aneuploidies that are screened for as part of prenatal care are Trisomy 21 (T21), 
 
1 Mollie A. Minear, Stephanie Alessi, Megan Allyse, Marsha Michie & Subhashini Chandrasekharan, Noninvasive 
Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues, 16 Annu. Rev. Genomics Hum. 




Trisomy 18 (T18) and Trisomy 13 (T13), and the majority of spontaneous miscarriages happen 
based on aneuploidies.4   Prenatal testing enables screening during pregnancy to detect women 
who are at high risk, followed by the option for a diagnostic test to confirm the presence of the 
genetic abnormality.5   
The origin of prenatal care in the United States began in the late 1800s as a preventative 
measure to decrease maternal and fetal mortality based on preeclampsia through routine 
measurement of blood pressure, urine and weight.6  Guidelines for prenatal care visits were 
established by the American College of Obstetricians and Gynecologists (ACOG) in 1989.7  The 
two types of prenatal testing are prenatal screening tests and prenatal diagnostic tests.  Prenatal 
screening techniques are offered to all pregnant women and include serum marker screening and 
ultrasound imaging in the first and second trimesters to detect birth defects, including 
chromosomal aneuploidies.8  The most comprehensive screening approach is integrated 
screening, which combines results from first and second trimester screening tests to calculate a 
single aneuploidy score.9   
While prenatal screening procedures calculate a risk of fetal aneuploidy, genetic 
diagnostic tests actually detect the presence of whole or sub-chromosomal genetic abnormalities 
through invasive measurement of amniotic fluid or placental tissue.10  Women who obtain a 
positive result from a screening test will be referred for diagnostic genetic testing through 
chorionic villus sampling (CVS) or amniocentesis.11  CVS is generally conducted in the first 
 
4 Megan E. Benoy, J. Igor Iruretagoyena, Laura E. Birkeland & Elizabeth M. Petty, The impact of insurance on 
equitable access to noninvasive prenatal screening (NIPT): private insurance may not pay , 12 J. Community Genet. 
185 (2021). 
5 Id. 
6 Judith A. Maloni, Ching-Yu Cheng, Cary P. Liebl & Sharp M. Jeanmarie, Transforming Prenatal Care: Reflections 
on the Past and Present with Implications for the Future, 25 JOGNN 17 (1996). 
7 Id. 





trimester (week 10 to 13), while amniocentesis is performed in the second trimester at week 15.12  
These invasive tests are the only diagnostic tests available for fetal aneuploidy and have a 1 in 
300 to 1 in 500 risk of pregnancy loss.13   
In 2011, based on advances in genetic technologies from the Human Genome Project, a 
new type of genetic screening test was introduced to the market called noninvasive prenatal 
testing (NIPT).14  NIPT involves a simple maternal blood draw to measure fetal fraction, which 
is the amount of cell-free fragments of fetal DNA (cffDNA) circulating in the maternal 
bloodstream from the placenta.15  NIPT screening is offered in the first trimester because the 
fetal fraction needs to be over 4 percent, which happens around the tenth week of pregnancy.16  
Compared to traditional first and second trimester screening, NIPT is more accurate with a lower 
false positive rate and an actual measurement (not an inferential aneuploidy risk score).17  False 
positive rates for NIPT range from 0.09% to 0.13% depending on the type of aneuploidy 
detected.18  The accuracy of NIPT greatly reduces the need for confirmatory follow up with 
invasive diagnostic testing.19  Currently NIPT is a second-line screening that is recommended 
following a positive conventional screening result, but there are efforts to adopt NIPT as a first -








18 Bin Yu, Bei-Yi Lu, Bin Zhang, Xiao-Qing Zhang, Ying-Ping Chen, Qin Zhou, Jian Jiang & Hui-Yan Wang, 
Overall evaluation of the clinical value of prenatal screening for fetal-free DNA in maternal blood, 96 Medicine 
(Baltimore) e7114 (2017).  
19 Id. 
20 Emilia Kostenko, Frederic Chantraine, Katleen Vandeweyer, Maximilian Schmid, Alex Lefevre, Deanna Hertz, 
Laura Zelle, Jose Luis Bartha & Gian Carlo Di Renzo, Clinical and Economic Impact of Adopting Noninvasive 
Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population , 45 
Fetal Diagn. Ther. 413 (2019). 
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 The NIPT global market in 2019 was valued at $2.95 billion and is expected to reach 
more than $10 billion by the end of 2027.21  NIPT tests are largely developed through 
commercial entities.  The first commercially available NIPT test was the MaterniT21 test (now 
MaterniT21 Plus) launched by Sequenom in 2011 to detect Trisomy 21.22   Sequenom reports 
that out-of-pocket costs for the MaterniT21 Plus test will be $235 for patients covered by 
insurance or $1700 for those without.23  Other commercial vendors who offer NIPT include 
Verinata (Verifi), Ariosa (Harmony), Natera (Panorama) and Illumina (VeriSeq).24  The list price 
of these different tests ranges from $1100 to $1590, while patient out-of-pocket fees can be from 
$200 to $400 depending on qualifying insurance.25 
 Multiple professional associations have issued guidelines on the adoption of NIPT.  
These organizations include the American College of Obstetricians and Gynecologists (ACOG), 
the Society for Maternal-Fetal Medicine (SMFM), the National Society of Genetic Counselors 
(NSGC), Stand up for Accurate Prenatal Answers (Stand up for APA) and the International 
Society for Prenatal Diagnosis (ISPD).26  These associations categorize pregnancies into two 
groups: high risk (15%) and average risk (85%).27  Prior to the August 2020 revised ACOG 
guidelines that recommended NIPT for all pregnant women, most organizations originally 
specified that NIPT should only be offered to women who were at high risk for fetal aneuploidies 
based on the following factors: maternal-age related risks, positive results on maternal serum-
screening, abnormal ultrasound, or prior affected pregnancy.28   Stand up APA advocated against 
age-related criteria, arguing that limiting NIPT access to women under 35 put them at higher risk 
 
21 Ashwin Agarwal, Lauren C. Sayres, Mildred K. Cho, Robert Cook-Deegan & Subhashini Chandrasekharan, 









of false positive and false negative results.29  False positive results lead to unnecessary, 
potentially stressful and expensive visits to specialists, while false negatives deny pregnant 
women the opportunity to plan and prepare accordingly.30 
Forty commercial insurance companies covered NIPT for all pregnancies even before the 
expanded ACOG recommendations in 2020.  But many state Medicaid programs and the two 
largest insurance companies – Aetna Inc. and United Healthcare (UHC) – did not cover NIPT for 
all pregnant women.31  Finally in December 2020, UHC expanded NIPT coverage for all 
pregnancies.32  Aetna temporarily expanded NIPT coverage to all pregnant women in response to 
the COVID-19 crisis but did not permanently expand access to all women until December 2020, 
after UHC changed its policy in response to the ACOG guidelines.33  Despite expanded access to 
NIPT, clinical guidelines emphasize that NIPT is a screening tool and not a diagnostic test . 
Confirmatory diagnostic testing should be performed and irrevocable decisions related to 
pregnancy should not be made based on NIPT alone.  However, the introduction of NIPT has 
corresponded to a reduction in diagnostic testing, which suggests that education by clinicians is 
critical to ensuring the accurate utilization of NIPT results.34   
 
29 Bloomberg Press, COVID-19: Aetna Expands NIPT Coverage for Young Pregnant Women, (May 2020), 
https://www.bloomberg.com/press-releases/2020-05-18/covid-19-aetna-expands-nipt-coverage-for-young-pregnant-
women (last visited February 6, 2021).   
30 Id. 
31 AISHEALTH, To Cover or Not to Cover? Prenatal DNA Test Creates Quandary for Payers , (January 2019), 
https://aishealth.com/health-plans/to-cover-or-not-to-cover-prenatal-dna-test-creates-quandary-for-payers/, (last 
visited February 6, 2021).   
32 PR Newswire, Stand Up for APA Applauds Aetna Decision to Permanently Cover Noninvasive Prenatal Testing 
(NIPT) For All Pregnant Women, (December 2020), https://www.prnewswire.com/news-releases/stand-up-for-apa-
applauds-aetna-decision-to-permanently-cover-noninvasive-prenatal-testing-nipt-for-all-pregnant-women-
301189663.html, (last visited February 6, 2021).   




Research indicates that women have a strong preference for NIPT, including a 2018 study 
that found NIPT uptake was increasing in women both above and below 35 years old.35  The key 
factors contributing to the support include accuracy of the results, alleviation of stress during 
pregnancy, and the ability to make value-based decisions without undergoing invasive diagnostic 
testing.36  Yet the expanded adoption of and support for NIPT has drawn concern from disability 
advocates who worry that routinization of NIPT will increase pressure to test and to terminate, 
resulting in fewer disabled births, a corresponding reduction in social services and an increase in 
stigmatization.37  For example, families with children with Down Syndrome (DS) express 
concern that widespread NIPT will reduce the number of DS births, thereby reducing public 
resources and support systems for DS families and shifting societal perceptions of children with 
disabilities.38   
Advancements in the field of genetic testing and genomics (the study of all genes) 
enabled the development of NIPT.39  As a genetic test, NIPT falls within the scope of public 
health genomics, a field defined in 2005 to oversee the “responsible and effective translation of 
genome-based knowledge and technologies for the benefit of the population.”40   Activities key 
to supporting public health include (1) enforcing laws and regulations that protect health and 
ensure safety, (2) developing policies and plans that support individual and community health 
efforts, (3) linking people to needed health services and (4) assuring a competent public and 
 
35 Celine Lewis, Melissa Hill & Lyn S. Chitty, Women’s experiences and preferences for service delivery of 
noninvasive prenatal testing for aneuploidy in a public health setting: a mixed methods study . 11 PLoS ONE 
e0153147 (2016).  
36 Sophie Montgomery & Zaneta M. Thayer, The influence of experiential knowledge and societal perceptions on 
decision-making regarding noninvasive prenatal testing (NIPT), 20 BMC Pregnancy and Childbirth, 630 (2020). 
37 Alexandra Cernat, Chante De Freitas, Umair Majid, Forum Trivedi, Caroline Higgins & Meredith Vanstone, 
Facilitating informed choice about noninvasive prenatal testing (NIPT): a systematic review and qualitative meta -
synthesis of women’s experiences, 19 BMC Pregnancy and Childbirth, 27 (2019). 
38 Id. 
39 Minear, supra note 1. 
40 Id. 
 9 
healthcare workforce.41  To reach these aims, this paper proposes the following measures.  First, 
expanded FDA oversight of NIPT is necessary to ensure that testing meets minimum 
performance standards and that marketing claims by commercial NIPT vendors are regulated.  
Second, as NIPT expands, public policy needs to recognize the impact on the disabled 
community by overseeing messaging about genetic disabilities. Third, increasing access to NIPT 
through expanded public insurance coverage will reduce healthcare inequities and ensure 
reproductive autonomy.  Finally, physicians have the responsibility to inform patients of the 
benefits and limitations of NIPT.  To minimize liability, physicians will depend on guidelines 
and educational resources from professional medical societies such as ACOG to ensure they are 
properly trained.  Incorporating these essential public health services for NIPT requires a 
coordinated government approach to ensure the responsible and equitable adoption of the 
technology.   
ANALYSIS 
Expanded FDA oversight of NIPT is necessary to ensure that testing meets minimum 
performance standards and marketing claims by commercial NIPT vendors are regulated 
Regulation of NIPT has sparked considerable recent debate as the adoption of the testing 
becomes more widespread.  Clinical tests that involve the analysis of human samples such as 
blood or saliva are classified as either in vitro diagnostics (IVDs) or laboratory developed tests 
(LDTs).42   IVDs are complete kits sold by manufacturers to laboratories adopting the assays, 
while LDTs are generally developed, marketed and run by a single laboratory for non-
commercial use.43  Since 1976, the Food and Drug Administration (FDA) has regulated IVDs 
 
41 Id. 
42 Pew Trust, Clinical Lab Tests Need Stronger FDA Oversight to Improve Patient Safety , (January 2021), 
https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/01/clinical-lab-tests-need-stronger-fda-
oversight-to-improve-patient-safety, (last visited February 16, 2021). 
43 Id. 
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under the Medical Device Amendments Act but has largely excluded LDTs from the stringent  
regulatory oversight that is required for IVDs. 44  Although LDTs are subject to FDA regulation, 
the agency has exercised “enforcement discretion” and chosen not to actively regulate LDTs.45  
The FDA’s position is that LDTs are generally intended for limited use within a restricted 
environment.46  IVDs and LDTs are also subject to oversight by the Centers for Medicare and 
Medicaid Services (CMS) through the 1988 Clinical Lab Improvement Amendments (CLIA), 
which is a federal regulatory standard that applies to clinical labs that perform basic testing on 
human samples.47    
FDA oversight of IVDs consists of premarket and post market controls.48  IVD products 
are classified into Class, I, II or III levels based on increasing levels of risk.49  The risk category 
determines the level of regulatory control and corresponding premarket FDA process required to 
bring the device to market.50  The possible premarket controls span from general controls to 510k 
clearance and premarket approval (PMA).51  510k clearance requires submitting documented 
evidence to the FDA that the medical device is substantially equivalent to a predicate device.52  
This evidence is evaluated by the FDA within 30 to 90 days.53  Premarket approval (PMA) is 
more in-depth than 510k and is used to evaluate the safety and effectiveness of Class III devices, 
which are those that “those that support or sustain human life, are of substantial importance in 
preventing impairment of human health, or which present a potential, unreasonable risk of illness 
 
44 Monica A. Lutgendorf, Katie A. Stoll, Dana M. Knutzen & Lisa M. Foglia, Noninvasive prenatal testing: 
limitations and unanswered questions, 16 Genet. Med. 281 (2014). 
45 Id. 
46 Hannah Mamuszka, The Neverending LDT vs IDT Debate, 6 J. Prec. Med. 1 (2019). 
47 Id. 
48 US. Food & Drug Admin., Overview of IVD Regulation, (September 2019), https://www.fda.gov/medical-
devices/ivd-regulatory-assistance/overview-ivd-regulation#9, (last visited April 25, 2021). 
49 Id. 
50 Id.  
51 Id. 
52 Greenlight Guru, 510k v PMA, (January 2021), https://www.greenlight.guru/glossary/510k-pma, (last visited 
April 25, 2021). 
53  Id. 
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or injury.”54  For IVDs subject to premarket approval (PMA), the FDA requires a research phase 
where the investigational use of the IVD is defined, the participation and consent of research 
subjects is overseen by institutional review boards (IRB), and analytical and clinical validation 
results as well as adverse results are reported.55  Once a PMA is submitted, the FDA has 180 
days to accept or reject the application.56   
Currently, the more than 40 NIPT solutions available on the market fall under the 
category of LDTs and not IVDs.57  The LDT classification means that NIPT manufacturers are 
not required to submit evidence of clinical validity to the FDA.58  They also avoid supervision of 
their marketing claims.59  The classification of NIPT as an LDT is insufficient oversight to tackle 
the possibility of false negative or false positive results.  Disability advocates such as the 
National Down Syndrome Society have questioned why the FDA does not provide more 
stringent oversight over NIPT, which is now being used routinely to make significant decisions 
about a pregnancy.60  NIPT is most appropriately used to screen for Down, Edwards and Patau 
syndromes and has been expanded in scope to identify extra or missing copies of the X and Y 
sex chromosomes.61  Yet the accuracy of NIPT depends on the type of chromosomal disorder 
that is being detected, and the technology is evolving to look at additional chromosomal 
 
54 US. Food & Drug Admin., Premarket Approval (PMA), (May 2019), https://www.fda.gov/medical-
devices/premarket-submissions/premarket-approval-pma, (last visited April 12, 2021).   
55 Id. 
56 Id. 
57 Jean Gakas, Sylvie Langlois, Vardit Ravitsky, Francois Audibert, David Gradus van der Berg, Hazarg Haidar & 
Francois Rousseau, Noninvasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical 




60 National Down Syndrome Society, Noninvasive Prenatal Tests (NIPTs), (January 2021),  
https://www.ndss.org/programs/ndss-legislative-agenda/healthcare-research/noninvasive-prenatal-tests-nipts, (last 
visited April 25, 2021). 
61 Medline Plus, What is noninvasive prenatal testing (NIPT) and what disorders can it screen for?  (November 
2020), https://medlineplus.gov/genetics/understanding/testing/nipt/ , (last visited April 25, 2021). 
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disorders that are based on variations in smaller regions of genetic material, such as changes in 
single genes or pieces of chromosomes.62   
Furthermore, NIPT was originally developed as a screening tool for high-risk 
pregnancies.  As its adoption spreads to the general pregnancy population, where the prevalence 
of trisomy is less than that for high-risk pregnancies, more studies and data need to be collected 
to evaluate the false positive and negative rate of the testing for average risk women.  A recent 
study found that the use of NIPT in the general population could return false positive results up 
to 20% of the time for Down syndrome and even higher rates for the detection of Edwards and 
Patau syndromes.63  From a policy perspective, sub-group analysis is critical as the accuracy of 
NIPT testing has been shown to be higher in high-risk pregnancies and more accurate for T21 
than T18 or T13.64 
There is evidence that some women consider NIPT diagnostic and do not realize it is a 
screening tool that precedes confirmatory diagnostic testing by CVS or amniocentesis.65  The 
concern is that pregnant women will make decisions about whether to continue a pregnancy 
based on incomplete results, or that they will be unprepared to raise a child with a chromosomal 
abnormality if they are faced with a false negative result.   This is where FDA oversight could 
lead to the development of standards that require test developers to define the target population, 
specify the intended use of the technology and demonstrate the analytical and clinical validity of 
the test, leading to a reduction in false positive and negative results.66  A recent survey of ACOG 
members reported that half of them favored more oversight of NIPT.67   
 
62 Id. 
63 Sian Taylor-Phillips, Karoline Freeman, Julia Geppert, Adeola Agbebiyi, Olalekan A. Uthman, Jason Madan, 
Angus Clarke, Siobhan Quenby & Aileen Clarke, Accuracy of noninvasive prenatal testing using cell-free DNA for 
detection of Down, Edwards and Patau syndromes: a systematic review and meta -analysis, 6 BMJ Open 1 (2016). 
64 Id. 
65 Pew Trust, supra note 42. 
66 Id. 
67 Minear, supra note 1.  
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There have also been calls for the FDA to regulate marketing and product use labels of 
NIPT by requiring claims about the tests to be truthful, non-misleading and scientifically 
robust.68  Advertisements may exaggerate the accuracy of the results and also promote the 
unapproved use of NIPT to screen for a broader range of chromosomal disorders, such as 
microdeletions underlying Cri-du-Chat or sex chromosome aneuploidies.69  Both individuals and 
their healthcare providers may lack sufficient information to understand the physical and 
cognitive characteristics associated with these genetic conditions.  They may disproportionately 
rely on content from commercial NIPT websites, who are in the business of marketing and 
selling the tests, and the concern is that the industry has paved the narrative about NIPT.70  The 
major concern with the misleading advertising is that women may be choosing to abort 
pregnancies based exclusively on NIPT results alone without pursuing diagnostic confirmatory 
testing or considering the potential false positive rates.   
In 2010, the FDA expressed a need for greater regulation of LDTs, and in 2014 it 
published two guidance documents describing potential efforts to enhance oversight.71  The 
proposals included a framework to Congress describing how the FDA would regulate LDTs, and 
they were eventually incorporated into the Diagnostic Accuracy and Innovation Act (DAIA).72  
This legislation evolved based on FDA revisions into the bipartisan Verifying Accurate Leading-
edge IVCT Development Act of 2020 (the VALID Act).73  The VALID Act includes multiple 
provisions aimed at increasing the stringency of LDT regulation by incorporating procedures 
 
68  Id. 
69 National Council on Disability, Genetic Testing and the Rush to Perfection: Part of the Bioethics and Disability 
Series, (October 2019), https://ncd.gov/sites/default/files/NCD_Genetic_Testing_Report_508.pdf , (last visited April 
25, 2021).  
70 Id. 
71 Potential Impact of the VALID Act on IVD Manufacturers, (March 2021), 
https://www.thejournalofprecisionmedicine.com/the-journal-of-precision-medicine/potential-impact-of-the-valid-




required through the IVD regulation process, such as ensuring the analytical and clinical validity 
of the tests.74  The goal is for the FDA to oversee a unified set of standards as it does with IVDs 
and to require evidence-based, truthful representation of product claims by testing 
manufacturers.75   
Specifically, the legislation includes a precertification requirement where one test within 
a test group would be subject to premarket approval (PMA) as is required for high-risk IVDs.76  
When applied to NIPT tests, the additional required documentation is key to establishing a 
record of efficacy about false positive and negative rates and to specifying the types of 
chromosomal disorders measured and reported.77  The challenge with the expanded process 
though is that it is time-consuming and costly and may be prohibitive for the smaller labs who 
can establish NIPT testing through the LDT route but may face obstacles of time and cost 
through the IVD PMA requirements.  The FDA does provide provisional approvals for IVDs 
which is a streamlined path for small labs to obtain PMA, but the provisional path was not 
included in the VALID Act for LDTs.78  Since the PMA approval is lengthy, a more viable 
alternative is to require NIPT manufacturers to apply for 510k clearance, which is currently 
required for Class II medical devices.79  Through this process, the NIPT companies demonstrate 
to the FDA that their low risk device is substantially equivalent (as safe and effective) as a 
device that is already on the market.80  The application and review process is less extensive and 
shorter than that required for PMA approval.  This approach may be a more reasonable step since 










oversight will address concerns while simultaneously supporting the rapid pace of innovation 
and adoption of NIPT.    
As NIPT expands, public policy needs to recognize the impact on the disabled community of 
messaging about genetic disabilities  
As prenatal genetic testing becomes more widespread, disability advocates have raised 
concerns that the growing adoption of NIPT reflects a negative valuation of individuals with 
disabilities.81  A major argument is that by simply offering prenatal screening, society is 
communicating an implicit bias against fetuses with genetic conditions.82  Yet advocacy for 
NIPT screening can coexist with support for the disabled.  Prenatal screening is not aimed at 
eliminating the birth of individuals with disabilities but instead assisting expecting families to 
make informed reproductive decisions.83  Nonetheless, the disabled community may 
understandably reject the notion that NIPT screening, and more significantly, the potential 
termination of pregnancies as a result, does not negatively impact the perception of those genetic 
conditions.  It is therefore important to recognize the position of these communities and ensure 
that their concerns are heard and addressed while simultaneously encouraging the responsible 
routinization of NIPT screening.   
A key concern raised about NIPT by disability advocates is that the number of Down 
Syndrome related pregnancies will decrease based on NIPT results as women choose to 
terminate the pregnancies.84  Older data from 1990 to 2010 showed that approximately 5300 
Down Syndrome babies were born annually from 2006-2010 and that the termination rate of 
 
81 Id. 
82 Minear, supra note 1. 
83 Eline M. Bunnik, Adriana Kater-Kuipers, Robert H. Galjaard & Inez D. de Beaufort, Should pregnant women be 
charged for noninvasive prenatal screening? Implications for reproductive autonomy and equal access, 46 J. Med. 
Ethics 194 (2020). 
84 Melissa Hill, Angela Barrett, Mahesh Choolani, Celine Lewis, Jane Fisher & Lyn S. Chitty, Has noninvasive 
prenatal testing impacted termination of pregnancy and live birth rates of infants with Down syndrome ?, 37 Prenat. 
Diagn. 1281 (2017). 
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Down Syndrome pregnancies was estimated at thirty percent.85  This study though predates the 
introduction of NIPT in 2011.  There is a need for continued examination of the impact of NIPT 
on elective terminations to ascertain what the actual outcome is on the birth of individuals with 
disabilities.  Critics of NIPT point to countries such as Iceland where almost 100% of women 
who receive a positive Down Syndrome result from prenatal screening choose to have abortions.  
The headlines read “Inside the country where Down Syndrome is Disappearing”86 and “A World 
Without Down Syndrome”87 and paint a picture that a pattern of requesting abortion on demand 
exists and that the birth of a child with Down Syndrome is devalued.   
Research indicates that women have a strong preference for NIPT.88  Since support for 
NIPT is high, public policies need to be adopted that establish a framework where resources for 
the disabled community continue to be available and prioritized.  The National Council on 
Disability (NCD) issued a 2019 report titled “Genetic Testing and the Rush to Perfection” with 
recommendations for Congress and federal authorities that are “aimed at greater federal and state 
oversight and quality control of genetic tests and improving genetic counselor education on 
disability.89  Genetic counselors can have a significant impact by understanding and presenting 
accurate information to expecting families.  In the 1980s, the life expectancy of a child born with 
Down Syndrome was 25 years, but it is now closer to 60-70 years.90  Specifically, the NCD 
recommended that the FDA end enforcement discretion and regulate NIPT.91  The NCD report 
stated that: 
 
85 Gert de Graaf, Frank Buckley & Brian G. Skotko, Estimates of the Live Births, Natural Losses, and Elective 
Terminations with Down Syndrome in the United States, 167 Am. J Med. Gen. 756 (2015). 
86Julian Quinones & Arijeta Lajka, What kind of society do you want to live in? Inside the country where Down 
syndrome is disappearing, (August 2017), https://www.cbsnews.com/news/down-syndrome-iceland/, (last visited 
March 18, 2021). 
87 Alison Gee, A world without Down’s syndrome?  (September 2016) https://www.bbc.com/news/magazine-
37500189, (last visited March 18, 2021).   
88 Lewis, supra note 35.   
89 National Council on Disability, supra note 69.  
90 Id. 
91 Id.  
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The FDA has identified problems with a number of LDTs, including claims that are not adequately 
supported by evidence, lack of appropriate controls yielding erroneous results, and in a few cases, 
falsification of data.    These problems demonstrated a need for greater FDA oversight to assure both 
analytical and clinical validity of LDTs relied on by physicians and patients. 92 
 
Furthermore, there is a call by the NCD for the Federal Trade Commission (FTC) to 
regulate the marketing claims and business practices of the genetic testing companies.93   For 
example, the FTC regulates the content of consumer advice on direct-to-consumer (DTC) genetic 
testing webpages, and the NCD’s position is that this oversight should be extended to prenatal 
genetic testing companies as well.94  Lastly, it is critical to have abundant resources available 
highlighting the meaningful life experiences of individuals with disabilities.  The federal 
PPDCAA (Prenatally and Postnatally Diagnosed Conditions Awareness Act) was a first step that 
was signed into law in October 2008 but has been largely unfunded.95  The aim of the legislation 
was to provide information to healthcare providers and families about living with genetic 
conditions and obtaining support, and nineteen states have adopted similar legislation.96  But the 
scope of the outreach varies state by state and efforts to collect data on rollout and efficacy are 
limited.97  
Increasing access to NIPT through expanded private and public insurance coverage will reduce 
healthcare inequities and ensure reproductive autonomy  
In the United States, health insurance coverage is predominantly available through 
commercial insurance providers and publicly funded insurance for those who meet certain 
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States, consisting of the group market (employer-sponsored insurance) and individual markets.99  
Public insurance programs include Medicaid, a joint federal-state program that finances medical 
services for low-income individuals, Medicare and TRICARE for military families.100 
Obstetricians have noted that the cost of NIPT is interfering with its incorporation into prenatal 
care.101 
The 2020 ACOG guidelines recommend unrestricted access to NIPT for low and high-
risk women.102  Prior to the update, forty commercial insurance companies covered NIPT for all 
pregnancies, but the two largest insurance companies, Aetna Inc. and United Healthcare (UHC), 
only covered high-risk pregnancies.103  In May 2020, Aetna temporarily expanded NIPT 
coverage to all pregnant women in response to the COVID-19 crisis but did not permanently 
expand access to all women until December 2020, after UHC changed its policy in response to 
the 2020 ACOG guidelines.104  Aetna and UHC joined Anthem, Cigna and other commercial 
insurance providers in efforts to ensure that NIPT coverage is provided for all expectant mothers, 
thereby enabling more than 90 percent of all women covered by private insurance to access 
NIPT.105  Despite the expansion of coverage, women who are covered by private insurance may 
still bear financial burdens associated with deductibles, co-pays or lack of coverage for certain 
genetic indications.106  NIPT is a better test than older screening methods for the detection of the 
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three major aneuploidies, but insufficient data are available about its reliability to capture rarer 
genetic conditions.107   
The United States does not have a national policy about what types of services 
government insurance programs must provide to pregnant women beyond inpatient and 
outpatient hospital care.108  The absence of formal federal guidance leaves discretion to the 
states.109  State Medicaid programs are the leading source of financing for births and are required 
to provide coverage of inpatient and outpatient hospital services for eligible women.110  But they 
have broad discretion on funding for broader categories of pregnancy-related services.111  
Developing a public policy framework for NIPT though is not neutral.112  If the government 
establishes policies to provide NIPT for free, governments may be seen as endorsing the 
screening, while copayment requirements may be viewed as discouraging the procedure.113  
There is evidence demonstrating the benefit of enabling women the choice to access NIPT by 
removing a payment barrier which diminishes the impact of external influences on a woman’s 
decision to pursue NIPT.114   
Interestingly, a recent study showed that low-risk women with government insurance are 
3.43 times more likely to obtain NIPT than equivalent risk woman covered by commercial 
insurance providers.115  Healthcare disparities are more apparent in low-income families, but 
when NIPT is covered for free by public insurance, women are more likely to utilize the 
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screening.116  On the other hand, women with private insurance are more influenced by cost 
when considering NIPT.117  It is interesting that women who do not face the same socioeconomic 
challenges are nonetheless experiencing inequity of NIPT adoption based on the cost.  This 
underscores the importance of promoting public funding of NIPT and influencing commercial 
companies to reduce the associated cost.   
While more than 90 percent of all women who are covered by private insurance can now 
access NIPT, the proportion of women who are covered for NIPT by public insurance through 
Medicaid is highly variable state by state.  Under state Medicaid programs, payment for 
laboratory tests is limited to those classified as medically necessary under each state’s medical 
assistance (MA) program.118  Therefore, advocacy for inclusion of NIPT as a medically 
necessary test will drive the rollout of availability for women.  Seven state Medicaid programs 
(AZ, ID, NE, NV, NM, RI, UT) and DC Medicaid have no coverage for NIPT, while twelve state 
Medicaid programs cover NIPT for all pregnancies (FL, IL, KY, MD, MN, ND, NJ, OH, OR, 
PA, VA, WA).   The remaining 31 states cover NIPT for high-risk pregnancies only.  Yet the 
state Medicaid programs are not the only target for test expansion.  To reduce administrative 
costs, Medicaid programs contract with managed care organizations (MCOs), and 69% of 
Medicaid beneficiaries are enrolled in a managed care plan.119  Reaching these organizations to 
expand NIPT coverage is also a critical step in increasing adoption, as MCO guidelines vary 
across different organizations.  MCOs may defer to state Medicaid guidelines or may establish 
their own parameters for covering NIPT, and this variability widens the coverage gap for women 
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MCO managing 216 thousand Medicaid lives but only covering NIPT for T21 for high-risk 
pregnancies.121  Molina Healthcare is a California-based MCO that also covers NIPT for high-
risk pregnancies but includes all aneuploidies.122   To address inequities in access to NIPT, 
ACOG has established a payment advocacy and policy portal where patients can submit tickets 
related to non-coverage, prior authorizations or payment issues.123  Conversion of state policies 
from no or specific coverage to unrestricted access will impact the ability of all expectant 
mothers to include NIPT in their prenatal care routine.    
California leads state public health efforts to accelerate availability of NIPT for expectant 
mothers.  In 2021, California’s Department of Public Health (CDPH) requested additional 
funding in its budget proposal to incorporate NIPT as a first-line instead of second-line screening 
for all pregnancies by 2022 through its CDPH Genetic Disease Screening Program (GDSP.)124  
The GDSP serves the people of California by providing programs to reduce the emotional and 
financial burden of disability and death caused by genetic and congenital disorders, and the 
proposal is intended to support: 
CDPH’s mission to advance the health and well-being of California’s diverse people and 
communities by optimizing the use of science and technology to improve health and by 
increasing health equity through universal access to the highest quality of care.125 
 
The CDPH recognizes that the use of NIPT has become more widely requested by pregnant 
patients and that it is more reliable with respect to false positive and detection rates.126  The 
proposal states that the follow up care managed by the Prenatal Screening Program (PNS) will be 
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reduced by 90% due to the lower false positive rate associated with NIPT, resulting in overall 
budget savings.127  If more states follow the California approach, then healthcare inequities for 
maternal care will be significantly reduced and families will be more informed and prepared to 
make reproductive decisions that are emotionally and financially manageable.   
Physicians have the responsibility to inform patients of the benefits and limitations of NIPT, but 
to minimize liability, physicians must also have guidelines and resources from professional 
medical societies such as ACOG to ensure they are properly trained on interpreting and 
communicating NIPT results to patients 
As more medical professionals incorporate genetic data into the scope of their practices 
and patient treatment plans, important questions are raised about how prepared they are to inform 
patients of benefits and potential risks associated with NIPT results.  Proponents of NIPT strive 
to make it the genetic screening standard of care for all pregnancies because it is a noninvasive 
accurate approach that reduces additional invasive testing associated with risks of fetal loss.128  
Physicians may face liability issues though if they fail to inform patients of the availability of 
NIPT or fail to communicate effectively the limitations in the results.129  For example, advances 
in NIPT technology will increase the types of genetic variation that can be detected early in a 
pregnancy.  Yet, the corresponding medical impact of those genetic variations will not match the 
pace of measurement.  This delay in clinical knowledge is a challenge for physicians who are not 
fully trained to analyze genetic data but are expected to interpret data and advise their patients.  It 
is critical that physicians have reliable, independent information about the limitations and impact 
 
127 Id. 




of NIPT testing so that they can effectively communicate the benefits and drawbacks to their 
patients.130 
Physicians have a legal obligation to treat their patients with the same reasonable care as 
other similarly situated physicians.131  Questions about the legal duties of physicians handling 
genetic data have recently been explored.132  The standard of care in prenatal surveillance is key 
to protecting physicians from liability.  To date, amniocentesis has been a gold standard in 
prenatal testing based on its high accuracy rate.  Physicians have a duty to disclose the risks and 
benefits of amniocentesis.  If a pregnant woman miscarries from this invasive testing, the 
physician would be protected for recommending a procedure that is consistent with the standard 
of care.133   With respect to NIPT, a physician could demonstrate that it is a reasonable medical 
practice in prenatal care - medical professional societies recommend the test and insurance 
companies cover its costs for all pregnanies.  NIPT is emerging as a standard of care, which is 
key to protecting physicians from liability.  However, if NIPT completely replaces amniocentesis 
and CVS as the standard of care, then physicians could be found negligent if they recommend 
invasive diagnostic tests that result in fetal loss.134  As standards of care change based on 
advancements in the fields of medicine and genetic testing, the liability landscape for physicians 
will change as well, since “it is the standard in place at the time the alleged negligence occurs 
that will be used to judge the physician’s conduct.”135   
Claims against physicians for prenatal medical negligence include wrongful birth claims 
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brought by families of a child with a congenital disease against the treating doctor.  The claim is 
that the doctor failed to warn that the child might be born with a serious genetic condition and 
that the family lost the opportunity to determine whether to terminate the pregnancy.137  
Currently 28 states recognize wrongful birth claims and 12 states prohibit them.138   To date there 
have not been any successful US lawsuits based on negligent administration of NIPT, but there 
have been for other screening methods.139  Recent wrongful birth actions include a NJ suit where 
a pregnant mother’s 21-week ultrasound was read as inconclusive but the child was born with 
Beckwith-Wiedemann syndrome.140  The mother claimed that she was deprived an option for an 
abortion because her physician failed to inform her of the possibility that the child might be born 
with a genetic disorder.141  The settlement awarded was $1,080,000.142  Another large settlement 
was approved in a recent medical malpractice suit involving prenatal screening.143  In this case, 
the plaintiff underwent a routine ultrasound and a “Quad Screen” test during her pregnancy that 
both reported normal results.144  She ended up giving birth to a child with Down Syndrome and 
brought suit against her physician.145  The plaintiff claimed that her physician violated the 
standard of care because she only communicated the normal results and failed to advise her on 
potential age-related risks or false negative results.146  Without additional guidance and context, 
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the plaintiff argued that she was denied the option for an abortion.147  The case was settlement 
awarded was $1,700,000.148  The settlements demonstrate the challenge of sending these cases 
through litigation because of the complexity of demonstrating that physicians failed their legal 
obligations to their patients and the challenge of quantifying the impact on the families.   
Based on these settlements for wrongful birth claims, it is likely that litigation in the 
NIPT space will emerge as the testing becomes more widespread.  Physicians who offer NIPT 
screening will have a duty to inform patients of the risks and benefits of the recommended 
interventions.  The associated risks are the possibility of false negative as well as false positive 
results.  It is currently unclear how liability in cases where a pregnancy is terminated based on 
false positive NIPT results will be handled and this will likely be an area of future consideration 
and debate.  The key to enforcing the duty of care is requiring physicians to obtain informed 
consent from patients when offering NIPT and to “disclose the material, special or unusual risks 
that a reasonable person in the patient’s position would want to know.”149   
The first published report of a false negative NIPT outcome was for a fetus that was 
postnatally diagnosed with Down Syndrome despite a negative NIPT result for Trisomy 21.150 
The pregnant mother chose NIPT over invasive diagnostic testing through amniocentesis, and 
received a negative result by the Verifi test for all three Trisomies tested (13, 18 and 21).151   
NIPT is not a diagnostic test.  Advertisements by NIPT vendors that that  convey greater than 
99% specificity and sensitivity may confuse patients into thinking that the results are completely 
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professionals need to be properly trained to knowledgably convey the utility of NIPT and to 
provide anticipatory guidance regarding possible outcomes.152   
Variable training in medical genetics and advances in testing and technology creates 
challenges for physicians who want to adopt NIPT as part of the prenatal standard of care. Eighty 
percent of obstetricians questioned about NIPT in a recent study expressed their desire that 
ACOG continue to develop guidelines and best practices for incorporating NIPT into routine 
care.153  When physicians are properly trained to understand the limitations and 
recommendations for NIPT, they can properly communicate those to their patients.  
As the medical community continues to embrace new technologies and incorporate them into daily 
clinical practice, it is imperative to ensure that the appropriate level of education is occurring for the 
provider ordering the test and the patient being offered the test. When knowledgeable medical 
professionals properly discuss the utility of NIPT and provide patients with anticipatory guidance 
regarding the possible outcomes, they enable the patient to make a more informed decision 
regarding the role of NIPT in their pregnancy.154 
 
Women prefer to learn about NIPT from their healthcare providers.155  It has been shown that 
even brief trainings on NIPT can have a positive impact on physician knowledge. In 2017, a 
United Kingdom study was conducted to determine physician confidence regarding NIPT after a 
40-minute training session.156  The results indicated a statistically significant increase in the 
number of participants who reported being more comfortable discussing NIPT with their 
patients.157  However, 65% of the respondents still missed key technical points about NIPT, 
including false positive rates and the source of DNA for the test.  The study authors concluded 
that a variety of educational formats are important to ensure reinforcement of the science and 











The development and adoption of NIPT as an accurate, noninvasive test early in 
pregnancy has expanded prenatal care by providing pregnant women the opportunity to screen 
for genetic disorders and make informed reproductive decisions early in their pregnancy.  Yet as 
a newer technology, NIPT requires a closer examination and evolving guidelines with respect to 
FDA regulation, messaging about disabilities, access through insurance and physician liability.   
Expanded FDA oversight of NIPT is necessary to ensure that testing meets minimum 
performance standards and marketing claims by commercial NIPT vendors are regulated .  As 
NIPT expands, public policy needs to recognize the impact on the disabled community and the 
messaging about genetic disabilities.  Increasing access to NIPT through expanded private and 
public insurance coverage will reduce healthcare inequities and ensure reproductive autonomy.  
Lastly, as NIPT is now part of the prenatal standard of care, physicians have the responsibility to 
inform patients of the benefits and limitations of the screening.  To do this effectively, healthcare 
professionals will need proper training to understand the technical basics and evolving scientific 
applications of NIPT and the impact on pregnancy decisions.   
 
 
  
 
 
